Results 251 to 260 of about 123,317 (298)

Fentanyl, Amphetamine-type Stimulants, Heroin, and xylazine in drug residues in two Northern border Mexican cities. [PDF]

Harm Reduct J
Bautista CF, Medina-Mora ME, Cruz SL, López-Brambila MA, Miranda-Soto V, Chávez D, Mata J, Chávez A, Segovia L, Angulo L, Slim S, Pacheco L.   +11 more
europepmc   +1 more source

Global burden and health inequalities of drug use disorders in adolescents and young adults from 1992 to 2021. [PDF]

Front Public Health
Bao R, Sun H, Zhang X, Zhao Z, Feng J, Jiang W.   +5 more
europepmc   +1 more source

Prescribed medications for patients with amphetamine-type stimulant use disorder seen in rural-serving Pacific Northwest primary care clinics. [PDF]

Addict Sci Clin Pract
Yerton MJ, McCabe CJ, Iles-Shih MD, Tsui JI, Hallgren KA.   +4 more
europepmc   +1 more source

Translatome of dorsal striatum parvalbumin interneurons revisited: insights across diverse experimental paradigms. [PDF]

Front Cell Neurosci
Naon C, Castell L, Thirard S, Moreno M, Rialle S, Goetz E, Casals E, Rogliardo A, Gut M, Esteve-Codina A, Quintana A, Bertaso F, Valjent E, Cutando L.   +13 more
europepmc   +1 more source

Global burden of amphetamine, cannabis, cocaine and opioid use in 204 countries, 1990–2023: a Global Burden of Disease Study

Jiseung Kang, Hyeon Jin Kim, Min Suk Kim, GBD 2023 Substance Use Collaborators, Jae Il Shin, Hasan Aalruz, Hedayat Abbastabar, Nasir Abbas, Mohammadreza Abbasian, Samar Abd ElHafeez, Ayele Mamo Abebe, Arash Abdollahi, Mohammad Abdollahi, Meriem Abdoun, Roberto Ariel Abeldaño Zuñiga, Richard Gyan Aboagye, Olumide Abiodun, Louis Kobina Dadzie, Dariush Abtahi, Ibrahim Jatau Abubakar, Bilyaminu Abubakar, Eman Abu-Gharbieh, Salahdein Aburuz, Ahmed Abu-Zaid, Mesafint Molla Adane, Prerna Agarwal, Olumide Thomas Adeleke, Habeeb Omoponle Adewuyi, Temitayo Esther Adeyeoluwa, Kishor Adhikari, Muhammad Sohail Afzal, Saira Afzal, Williams Agyemang-Duah, Aqeel Ahmad, Sajjad Ahmad, Danish Ahmad, Ali Ahmadi, Syed Anees Ahmed, Haroon Ahmed, Muktar Beshir Ahmed, Ayman Ahmed, Mehrunnisha Sharif Ahmed, Yazan A. Al‐Ajlouni, Muaaz Alajlani, Rasmieh Al‐Amer, Mohammed ALBashtawy, Wafa Ali Aldhaleei, Abdelazeem M. Algammal, Fadwa Naji Alhalaiqa, Mohammed Usman Ali, Liaqat Ali, Syed Shujait Ali, Mohammad Daud Ali, Sheikh Mohammad Alif, Samah W. Al-Jabi, Ahmad Alrawashdeh, Rami H Hani Al-Rifai, Sahel Majed Alrousan, Najim Alshahrani, Alaa B. Al-Tammemi, Yazan Al Thaher, Nelson Alvis-Guzmán, Mohammad Al-Wardat, Yaser Mohammed Al-Worafi, Hany Aly, Karem H. Alzoubi, Walid A. Al-Zyoud, Sohrab Amiri, Mohammad Amrollahi-Sharifabadi, Deanna Anderlini, Abhishek Anil, Carl Abelardo T. Antonio, Catherine M. Antony, Saeid Anvari, Boluwatife Stephen Anuoluwa, Jalal Arabloo, Ana Margarida Araújo, Irfan Ardani, Demelash Areda, Benedetta Armocida, Mahwish Arooj, Anton A Artamonov, Tahira Ashraf, Tahira Ashraf, Muhammad Shahzad Aslam, Seyyed Shamsadin Athari, A. Atreya, Avinash Aujayeb, Lemessa Assefa A. Ayana, Ahmed Y. Azzam, Nayereh Baghcheghi, Sara Bagheri, Razieh Bahreini, Ruhai Bai, Atif Amin Baig, Maciej Banach, Mehmet Firat Baran, Mainak Bardhan, Hiba Jawdat Barqawiil, Amadou Barrow   +99 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Amphetamine metabolism in amphetamine psychosis

Clinical Pharmacology & Therapeutics, 1973
The metabolism of 3H‐d,l‐amphetamine was investigated in 11 subjects with amphetamine psychosis. In 3 patients with acidic urine (pH < 6.6), renal elimination of unchanged amphetamine (67% to 73%) was associated with plasma half‐life of 7 to 14 hours and rapid clearing of psychotic symptoms.
E, Anggård, L E, Jönsson, A L, Hogmark, L M, Gunne   +3 more
openaire   +2 more sources